Intra-Cellular Therapies Inc
Change company Symbol lookup
Select an option...
ITCI Intra-Cellular Therapies Inc
EAD Allspring Income Opportunities Fund
IMTE Integrated Media Technology Ltd
LIN Linde PLC
XP XP Inc
SENEA Seneca Foods Corp
LEU Centrus Energy Corp
IFF International Flavors & Fragrances Inc
$NQCAPSTN The Capital Strength Net Total Retur
XFLT XAI Octagon Floating Rate & Alternative Income Term Trust
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Closing Price
$55.17
Day's Change
-1.91 (-3.35%)
Bid
--
Ask
--
B/A Size
--
Day's High
57.12
Day's Low
53.13
Volume
(Average)
Volume:
896,511

10-day average volume:
920,000
896,511

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.